ABSTRACT
Based on data from randomized controlled trials over the past decade, oral mycophenolate (CellCept) now rivals intravenous cyclophosphamide (Cytoxan) as a first-line therapy for lupus nephritis, offering similar efficacy but less toxicity. The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all.
Footnotes
* Dr. Appel has disclosed that he has consulted for Vifor Pharma (formerly Aspreva Pharmaceuticals Corp) and has consulted, taught, spoken, and served on advisory committees or review panels for and received research grants from Genentech.
- Copyright © 2012 The Cleveland Clinic Foundation. All Rights Reserved.